The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours.

Response to paper by Kelly et al "The opioid receptor pharmacology of GSK1521498 compared to other ligands with different effects on compulsive reward-related behaviors" published in Psychopharmacology 232, 305-314, 2014. Psychopharmacology (Berl) (2015) 1.05

The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice. Psychopharmacology (Berl) (2015) 0.79

Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype. Neuropsychopharmacology (2016) 0.76

The Novel μ-Opioid Receptor Antagonist GSK1521498 Decreases Both Alcohol Seeking and Drinking: Evidence from a New Preclinical Model of Alcohol Seeking. Neuropsychopharmacology (2015) 0.76

Obesity: Current and potential pharmacotherapeutics and targets. Pharmacol Ther (2016) 0.75

Reply to Wang and Sadée. Psychopharmacology (Berl) (2015) 0.75

Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev (2013) 2.42

Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer. Nature (2001) 2.28

Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology (2010) 1.97

75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol (2006) 1.91

In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. J Pharmacol Exp Ther (2005) 1.54

Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. J Neurochem (2001) 1.53

Role of protein kinase C and mu-opioid receptor (MOPr) desensitization in tolerance to morphine in rat locus coeruleus neurons. Eur J Neurosci (2009) 1.34

Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence. J Pharmacol Exp Ther (2003) 1.32

Beta-arrestin2 and c-Src regulate the constitutive activity and recycling of mu opioid receptors in dorsal root ganglion neurons. J Neurosci (2007) 1.30

A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence. Synapse (2007) 1.24

Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment. Mol Pharmacol (2001) 1.24

Opioid tolerance in periaqueductal gray neurons isolated from mice chronically treated with morphine. Br J Pharmacol (2005) 1.16

Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Ther (2007) 1.16

Continued morphine modulation of calcium channel currents in acutely isolated locus coeruleus neurons from morphine-dependent rats. Br J Pharmacol (1999) 1.13

Chronic exposure to morphine does not induce dependence at the level of the calcium channel current in human SH-SY5Y cells. Neuroscience (1992) 1.12

Delta opioid modulation of the binding of guanosine-5'-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects. J Pharmacol Exp Ther (1997) 1.12

G-protein coupling of mu-opioid receptors (OP3): elevated basal signalling activity. Biochem J (2000) 1.10

Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonist. J Pharmacol Exp Ther (2011) 1.07

Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor. Proc Natl Acad Sci U S A (2013) 1.06

Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating. Neuropsychopharmacology (2012) 1.02

Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor. Br J Pharmacol (2009) 0.99

Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist. J Clin Pharmacol (2011) 0.98

Relationship of brain morphine levels to analgesic activity in acutely treated mice and rats and in pellet implanted mice. J Pharmacol Exp Ther (1975) 0.98

Opioid receptor-coupled G-proteins in rat locus coeruleus membranes: decrease in activity after chronic morphine treatment. Brain Res (1997) 0.97

Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor. Synapse (2010) 0.97

Constitutively active mu-opioid receptors inhibit adenylyl cyclase activity in intact cells and activate G-proteins differently than the agonist [D-Ala2,N-MePhe4,Gly-ol5]enkephalin. J Biol Chem (2001) 0.96

Attenuation of cocaine and heroin seeking by μ-opioid receptor antagonism. Psychopharmacology (Berl) (2013) 0.94

Analgesic tone conferred by constitutively active mu opioid receptors in mice lacking β-arrestin 2. Mol Pain (2011) 0.93

Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the μ-opioid receptor inverse agonist GSK1521498. J Clin Pharmacol (2011) 0.92

Enhanced spontaneous activity of the mu opioid receptor by cysteine mutations: characterization of a tool for inverse agonist screening. BMC Pharmacol (2003) 0.92

Constitutively active μ-opioid receptors. Methods Enzymol (2010) 0.90

Label-free monitoring of μ-opioid receptor-mediated signaling. Mol Pharmacol (2014) 0.80

The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol (2015) 5.96

A prescription for better prescribing. BMJ (2006) 5.31

Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet (2003) 4.91

Neural substrates for voluntary suppression of negative affect: a functional magnetic resonance imaging study. Biol Psychiatry (2005) 4.84

Whole-brain anatomical networks: does the choice of nodes matter? Neuroimage (2009) 4.43

The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol (2015) 4.28

Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry (2004) 3.85

Network-based statistic: identifying differences in brain networks. Neuroimage (2010) 3.60

Amygdala-frontal connectivity during emotion regulation. Soc Cogn Affect Neurosci (2007) 3.43

Does alcohol increase the risk of overdose death: the need for a translational approach. Addiction (2008) 3.39

Association between amygdala hyperactivity to harsh faces and severity of social anxiety in generalized social phobia. Biol Psychiatry (2005) 3.35

Human brain networks in health and disease. Curr Opin Neurol (2009) 3.28

Modular and hierarchically modular organization of brain networks. Front Neurosci (2010) 3.06

Abnormal brain structure implicated in stimulant drug addiction. Science (2012) 2.85

Hierarchical modularity in human brain functional networks. Front Neuroinform (2009) 2.76

The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol (2015) 2.74

Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology (2009) 2.60

Schizophrenia, neuroimaging and connectomics. Neuroimage (2012) 2.49

Beyond threat: amygdala reactivity across multiple expressions of facial affect. Neuroimage (2005) 2.47

Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov (2012) 2.44

Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev (2013) 2.42

Efficient physical embedding of topologically complex information processing networks in brains and computer circuits. PLoS Comput Biol (2010) 2.37

Disrupted modularity and local connectivity of brain functional networks in childhood-onset schizophrenia. Front Syst Neurosci (2010) 2.22

Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science (2008) 2.20

The Concise Guide to PHARMACOLOGY 2015/16: Overview. Br J Pharmacol (2015) 2.13

Drug addiction endophenotypes: impulsive versus sensation-seeking personality traits. Biol Psychiatry (2010) 2.13

Network scaling effects in graph analytic studies of human resting-state FMRI data. Front Syst Neurosci (2010) 2.13

Disrupted axonal fiber connectivity in schizophrenia. Biol Psychiatry (2010) 2.12

Cognitive fitness of cost-efficient brain functional networks. Proc Natl Acad Sci U S A (2009) 2.07

Fetal testosterone influences sexually dimorphic gray matter in the human brain. J Neurosci (2012) 2.05

Cognitive dysfunction and anxious-impulsive personality traits are endophenotypes for drug dependence. Am J Psychiatry (2012) 2.05

Differential activation of the amygdala and the 'social brain' during fearful face-processing in Asperger Syndrome. Neuropsychologia (2006) 2.02

Abnormal structure of frontostriatal brain systems is associated with aspects of impulsivity and compulsivity in cocaine dependence. Brain (2011) 2.00

Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacology (2010) 1.98

Applications of fMRI in translational medicine and clinical practice. Nat Rev Neurosci (2006) 1.95

The rich club of the C. elegans neuronal connectome. J Neurosci (2013) 1.92

Cognitive effort drives workspace configuration of human brain functional networks. J Neurosci (2011) 1.92

Neural responses to happy facial expressions in major depression following antidepressant treatment. Am J Psychiatry (2007) 1.92

75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol (2006) 1.91

BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci (2013) 1.91

Genetic influences on cost-efficient organization of human cortical functional networks. J Neurosci (2011) 1.90

Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biol Psychiatry (2008) 1.89

The Concise Guide to PHARMACOLOGY 2015/16: Voltage-gated ion channels. Br J Pharmacol (2015) 1.88

Association of genetic risks for schizophrenia and bipolar disorder with specific and generic brain structural endophenotypes. Arch Gen Psychiatry (2004) 1.87

Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol (2006) 1.87

μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol (2010) 1.83

Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. Br J Clin Pharmacol (2008) 1.83

Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, and psychosis. Arch Gen Psychiatry (2006) 1.78

Atypical neural self-representation in autism. Brain (2009) 1.73

Impaired cognitive flexibility and motor inhibition in unaffected first-degree relatives of patients with obsessive-compulsive disorder. Am J Psychiatry (2007) 1.71

A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis. Blood (2009) 1.70

Shared neural circuits for mentalizing about the self and others. J Cogn Neurosci (2010) 1.67

The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br J Pharmacol (2015) 1.66

Prediction error during retrospective revaluation of causal associations in humans: fMRI evidence in favor of an associative model of learning. Neuron (2004) 1.64

Simple models of human brain functional networks. Proc Natl Acad Sci U S A (2012) 1.63

The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. Br J Pharmacol (2015) 1.62

Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One (2010) 1.62

Functional dysconnectivity in schizophrenia associated with attentional modulation of motor function. Brain (2005) 1.61

What can spontaneous fluctuations of the blood oxygenation-level-dependent signal tell us about psychiatric disorders? Curr Opin Psychiatry (2010) 1.57

The relationship between motor deficit and hemisphere activation balance after stroke: A 3T fMRI study. Neuroimage (2006) 1.55

The anatomical distance of functional connections predicts brain network topology in health and schizophrenia. Cereb Cortex (2012) 1.55

Endogenous human brain dynamics recover slowly following cognitive effort. PLoS One (2009) 1.55

Poor prescribing is continual. BMJ (2006) 1.55

Reproducibility of graph metrics of human brain functional networks. Neuroimage (2009) 1.54

General and specific functional connectivity disturbances in first-episode schizophrenia during cognitive control performance. Biol Psychiatry (2011) 1.54

Change detection in children with autism: an auditory event-related fMRI study. Neuroimage (2005) 1.52

The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. Int J Neuropsychopharmacol (2012) 1.52

Mu-opioid receptor desensitization in mature rat neurons: lack of interaction between DAMGO and morphine. J Neurosci (2003) 1.51

Cognitive relevance of the community structure of the human brain functional coactivation network. Proc Natl Acad Sci U S A (2013) 1.49

Brain hyper-reactivity to auditory novel targets in children with high-functioning autism. Brain (2008) 1.49

Quantitative multi-parameter mapping of R1, PD(*), MT, and R2(*) at 3T: a multi-center validation. Front Neurosci (2013) 1.45

Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry (2006) 1.44

Task instructions modulate neural responses to fearful facial expressions. Biol Psychiatry (2003) 1.43

Biological sex affects the neurobiology of autism. Brain (2013) 1.40

Protein kinase C activation enhances morphine-induced rapid desensitization of mu-opioid receptors in mature rat locus ceruleus neurons. Mol Pharmacol (2004) 1.39

Brain surface anatomy in adults with autism: the relationship between surface area, cortical thickness, and autistic symptoms. JAMA Psychiatry (2013) 1.35

Regional brain morphometry in patients with schizophrenia or bipolar disorder and their unaffected relatives. Am J Psychiatry (2006) 1.35

Validation of a quantitative magnetic resonance method for measuring human body composition. Obesity (Silver Spring) (2008) 1.34

Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans. Synapse (2008) 1.34

Integrated strategy for improving functional connectivity mapping using multiecho fMRI. Proc Natl Acad Sci U S A (2013) 1.32

How important is protein kinase C in mu-opioid receptor desensitization and morphine tolerance? Trends Pharmacol Sci (2006) 1.32

Hubs of brain functional networks are radically reorganized in comatose patients. Proc Natl Acad Sci U S A (2012) 1.31

Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors. J Pharmacol Exp Ther (2010) 1.30

Learning-related human brain activations reflecting individual finances. Neuron (2007) 1.30

The Concise Guide to PHARMACOLOGY 2015/16: Ligand-gated ion channels. Br J Pharmacol (2015) 1.30

Specialization of right temporo-parietal junction for mentalizing and its relation to social impairments in autism. Neuroimage (2011) 1.27

Procedural learning in schizophrenia: a functional magnetic resonance imaging investigation. Schizophr Res (2002) 1.27

P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. Blood (2005) 1.26

Connectomic intermediate phenotypes for psychiatric disorders. Front Psychiatry (2012) 1.26

Amygdala and insula response to emotional images in patients with generalized social anxiety disorder. J Psychiatry Neurosci (2009) 1.25

Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets. Blood (2004) 1.25

Functional dysconnectivity of corticostriatal circuitry as a risk phenotype for psychosis. JAMA Psychiatry (2013) 1.25

A computational morphometric MRI study of schizophrenia: effects of hallucinations. Cereb Cortex (2002) 1.18

Distinct modulatory effects of satiety and sibutramine on brain responses to food images in humans: a double dissociation across hypothalamus, amygdala, and ventral striatum. J Neurosci (2010) 1.18

Influence of compulsivity of drug abuse on dopaminergic modulation of attentional bias in stimulant dependence. Arch Gen Psychiatry (2010) 1.17